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β-Cryptoxanthin (β-CRX) is a carotenoid found in human blood. It is speciﬁcally rich in Sat-
suma mandarin (Citrus unshiu Marc.) but very little in other fruits or vegetables. Several
reports indicate the health promoting beneﬁts of β-CRX. As we had reported visceral fat
reduction on mildly obese male by the oral administration of β-CRX, a detailed mecha-
nism has not been identiﬁed. To identify the mechanism, obese model mouse, TSOD was
used in the present study. Oral administration of β-CRX repressed body weight, abdomi-
nal adipose tissue weight, and serum lipid concentrations onTSOD mice.The outstanding
observation is the signiﬁcant repression of adipocyte hypertrophy. DNA microarray analy-
sis strongly indicates that the oral administration of β-CRX represses the inﬂammatory
cytokine secretion and improves the lipid metabolism and the energy consumption. It
also suggests these effects are partly mediated by PPAR-α, not only lipid metabolism and
adipocyte differentiation control but possibly internal circadian clock modulation.
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INTRODUCTION
Nutritional importance of carotenoids is now widely accepted.
They are known as natural antioxidants and anti-cancer effectors
(Smith, 1998; Young and Lowe, 2001). In most cases carotenoid
means β-carotene, lutein, or lycopene and the functional analysis
of the other minor carotenoids are not fairly evaluated.
β-Cryptoxanthin (β-CRX) is one of the carotenoids classi-
ﬁed into xanthophyll and found in human blood together with
α-carotene, β-carotene, lycopene, lutein, and zeaxanthin. Unlike
other abundant carotenoids, β-CRX is not found in most fruits or
vegetables but in speciﬁc ones; hot pepper,persimmon,or Satsuma
mandarin (Citrus unshiu Marc.; Mangels et al., 1993).
Satsuma mandarin, also known as table orange or Satsuma
in western countries, is one of the most popular citrus in Japan.
It is sweet, tasty, and rich in vitamin C. It is notable that Sat-
suma mandarin is one of the most β-CRX rich fruits in the
world. An edible part of Satsuma mandarin contains about
1.8mg/100 g of β-CRX, while it is 0.2mg/100 g in Valencia orange
and almost nothing in grapefruits. As β-CRX is rarely found in
most fruits or vegetable, serum β-CRX concentration is almost
parallel to the Satsuma mandarin consumption in Japanese popu-
lation and is higher than western populations (Sugiura et al., 2002,
2004a).
As nutritional functions or metabolisms of abundant
carotenoids, e.g., β-carotene or lycopene, are well studied (Kaplan
et al., 1990; Cooney et al., 1991; Nair et al., 1996; Glise et al.,
1998; Bramlev, 2000), those of β-CRX were not examined enough.
Recent reports strongly suggest the important functions of β-
CRX. They showed signiﬁcant negative correlation between serum
β-CRX concentrations and disease morbidity such as liver dis-
order (Sugiura et al., 2005, 2006a), cancer (Rauscher et al.,
1998; Nishino et al., 2000; Tanaka et al., 2000), post-menopausal
osteoporosis (Uchiyama and Yamaguchi, 2006; Sugiura et al.,
2008, 2011), and diabetes (Sugiura et al., 2006b,c). These results
strongly indicate β-CRX intake is beneﬁcial for the human
health.
Obesity is one of the most major symptoms of metabolic syn-
drome and the visceral fat accumulation causes many bad effects.
Previous study suggests that β-CRX could normalize the serum
lipid level (Sugiura et al., 2004b). We already showed the contin-
uous β-CRX oral intake may improve the symptoms of metabolic
syndrome, such as visceral adipose tissue, body weight, and waist
circumference reduction in mildly obese males (Tsuchida et al.,
2008). But we still do not know the mechanism how β-CRX would
prevent obese and metabolic syndrome.
In this report, we investigated how β-CRX would prevent the
symptoms of metabolic syndrome using obese model mouse,
TSOD (Tsumura Suzuki obese diabetes; Hirayama et al., 1999;
Suzuki et al., 1999), which accumulates visceral fat rapidly after
4 weeks old and shows similar symptoms of human metabolic
syndrome.
MATERIALS AND METHODS
β-CRYPTOXANTHIN
Enzyme processed Satsuma mandarin (EPSM) manufactured by
UNITIKA Ltd. (Osaka, Japan) was used as the source of β-CRX. It
is orange powder made from Satsuma mandarin pulp after juicing
and contains minimum 0.2% (w/w) β-CRX.
TSOD AND TSNO MICE
Male, 3 weeks old TSOD (Tsumura Suzuki obese, diabetes) and
the genetic control (Tsumura Suzuki non-obese, diabetes, TSNO)
mice were obtained from Institute for Animal Reproduction
(Ibaraki, Japan). After a week acclimatization period, each mice
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were divided into Experimental groups and Control groups,
denoted TSOD-E, TSOD-C, TSNO-E, and TSNO-C respectively
(n = 6 in each).Olive oil-suspendedEPSM,at 400mg/kg/day,were
orally administrated as β-CRX on Experimental groups (TSOD-E
andTSNO-E),equivalent to 0.8mgβ-CRX/kg/day.Control groups
(TSOD-C and TSNO-C) were administrated olive oil only.
Each group of mice were housed in one cage under 12 h light
and 12 h dark cycle and fed Labo MR Stock (Nosan; Kanagawa,
Japan). Body weight, food, and water consumption were moni-
tored during the experimental period. The experimental period
was 8weeks. Three adipose tissues (epididymal, perirenal, and
mesenteric adipose tissues), liver, femoral muscle, and serum were
isolated after the experimental period.
This experiment was approved and carried out in accordance
with the UNITIKA’s Guidelines for Animal Experimentation,
which are based on the notiﬁcation of the Ministry of Education,
Culture, Sports, Science, and Technology, Japan.
SERUM LIPID ASSAY
Three kinds of serum lipid concentrations, triglyceride (TG), total
cholesterol (TC), and non-esteriﬁed fatty acid (NEFA) were ana-
lyzed using diagnosis kit (Wako; Osaka, Japan) following to the
manufactures’ instruction.
ADIPOSE TISSUE ANALYSIS
Epididymal adipose tissueswere ﬁxed in formalin,parafﬁn embed-
ded and sectioned, following hematoxylin–eosin (HE) staining.
The area of adipocytes was analyzed under microscope and
Image Pro Discovery computer-assisted analysis system (Media
Cybernetics, Inc.; Bethesda, MD, USA).
DNA MICROARRAY ANALYSIS
Isolated epididymal adipose tissue, liver, and femoral muscle were
quickly placed in RNAlater (Ambion Inc., TX, USA) and kept
in deep freezer (−80˚C) until needed. Total RNA was isolated
from those tissues using RNeasy kit (QIAGEN, Tokyo, Japan)
according to the manufacture’s manual. Biotin-labeled cRNA was
synthesized and fragmented using GeneChip 3′-IVT labeling kit
(Affymetrix, Tokyo, Japan). Fragmented cRNA was hybridized
at 45˚C for 16 h to a GeneChip Mouse Genome 430A 2.0 Array
(Affymetrix). Gene chips were washed and stained using ﬂuid sta-
tion and scanned using GeneChip scanner 300 7G (Affymetrix).
Data were analyzed by Expression Console (Affymetrix) and
imported into ArrayStar software (DNAstar). For biological inter-
pretation of the differentially expressed genes, the database for
annotation, visualization, and integrated discovery (DAVID) v6.2
was used (Huang et al., 2009)1. GO biological processes with
p < 0.01were considered to be signiﬁcantly changed.Differentially
expressed genes were also categorized and mapped onto pathway
using KEGG tools (Kanehisa, 1997)2.
STATISTICAL ANALYSIS
All data are shownasmean± SD.Datawere analyzedusing student
T test and p values< 0.05 were considered statistically signiﬁcant.
1http://david.abcc.ncifcrf.gov/
2http://www.genome.jp/kegg/
RESULTS
BODY WEIGHT
The body weights on each group during the experimental period
are shown in Figure 1. There was no difference on body weight
between TSNO-E and TSNO-C. The average weight of TSOD-C
is signiﬁcantly higher than TSNO-C, because of the difference of
genetic background.
The body weight of TSOD-E was signiﬁcantly repressed com-
pared to TSOD-C. It was statistically signiﬁcant after the second
week. As food and water consumption on TSOD-E and TSOD-C
during the experimental period were almost the same (data not
shown), those differences were not due to the energy intake but
the β-CRX administration.
As β-CRX consumption did not affect the body weight of non-
obese mice, TSNO, it was suggested that β-CRX may contribute to
body weight reduction only in obese individuals.
SERUM LIPIDS
The serum concentrations of TC, NEFA, and TG were assayed and
the results are shown in Figure 2.
There were no differences between TSNO-E and TSNO-C in
all three serum lipid concentrations and they signiﬁcantly ele-
vated in TSOD-C. β-CRX administration on TSOD resulted in
the repression of the serum lipid elevation. TG and NEFA concen-
trations in TSOD-E declined signiﬁcantly compared to TSOD-C
and repressed to the same level as non-obese control, TSNO-
E. Although TC concentration in TSOD-E was also signiﬁcantly
repressed compared to TSOD-C, it was still signiﬁcantly higher
than TSNO-E.
β-CRX administration signiﬁcantly repressed the elevation of
serum lipid concentrations in obese mice, TSOD, while it did
not affect the normal mice, TSNO. These results indicate β-CRX
administration normalizes serum lipid rather than repressing their
elevation.
FIGURE 1 | Comparisons of body weights. Closed circles, open circles,
closed triangles, and open triangles denoteTSOD-E, TSOD-C, TSNO-E, and
TSNO-C respectively. Asterisks indicate statistical signiﬁcance between
Experimental group and Control group onTSOD; one, two, and three
asterisks indicate the p value less than 0.05, 0.01, and 0.005, respectively.
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LIVER AND ADIPOSE TISSUES ANALYSIS
Liver weights were compared between the groups (Figure 3).
There were no difference between TSNO-E and TSNO-C, while
the weight of TSOD-C was signiﬁcantly higher than those of
TSNOs. Though the weight of TSOD-E was still higher than those
of TSNOs, it was signiﬁcantly reduced compared to TSOD-C.
Those indicate obese-induced liver hypertrophy was repressed by
the administration of β-CRX.
Similar tendency was observed in three adipose tissue weights;
epididymal, perirenal and mesenteric adipose tissues (Figure 4).
Each adipose tissue weight in TSOD-E reduced to 86, 80, and
74% respectively compared to TSOD-C and the total weight
reduced to 81%. The weight reduction of mesenteric adipose
tissue, commonly called intraperitoneal adipose tissue, was the
greatest among them.
FIGURE 2 | Comparisons of serum lipids. SerumTG, TC, and NEFA
concentrations were assayed. One and two asterisks indicate the p value
less than 0.05 and 0.01, respectively and NS indicate no signiﬁcance
between the groups.
FIGURE 3 | Comparisons of liver weights.Two asterisks indicate the p
value less than 0.01 and NS indicate no signiﬁcance between the groups.
Histocytological microscopic specimens were prepared from
epididymal adipose tissues.Figure 5 shows themicroscopic images
of each adipocyte. The size of adipocyte on TSNO-E and TSNO-
C looked almost the same. Although it enlarged signiﬁcantly on
TSOD-C, it reduced on TSOD-E.
The average areas of each adipocyte were calculated to evaluate
them objectively (Figure 6). The average areas of TSNO-E and
TSNO-C were not different, while it was signiﬁcantly enlarged
on TSOD-C. Compared to TSOD-C, it was signiﬁcantly reduced
on TSOD-E. These observations showed mature adipocytes on
TSOD were hypertrophic compared to those on TSNO. But the
administration of β-CRX may prevent adipocyte hypertrophy and
normalize them.
FIGURE 4 |Weights of visceral adipose tissues.Three visceral adipose
tissues, epididymal (Epi.), perirenal (Peri.), and mesenteric (Mes.) adipose
tissues, were removed and the weights were compared. Percentages in
the column of TSOD-E represent the rate of weight reduction compared to
TSOD-C. Statistic difference was analyzed against total weight of three
tissues; two asterisks indicate the p value less than 0.01 and NS indicates
no signiﬁcance between the groups.
FIGURE 5 | Size of each adipocyte. (A–D) represent HE-stained
epididymal adipose tissue section derived fromTSNO-C, TSNO-E, TSOD-C,
andTSOD-E respectively.
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FIGURE 6 | Comparisons of individual adipose area. Average areas of
each epididymal cell were calculated and compared. Two asterisks indicate
the p value less than 0.01 and NS indicate no signiﬁcance between the
groups.
MICROARRAY ANALYSIS
The effect of β-CRX on gene expression on TSOD mouse was eval-
uated by Affymetrix microarray analysis (Table 1). The number of
genes that the expression ﬂuctuating more than two-times both
between the TSOD-C and TSNO-C, and between the TSOD-C
and TSOD-E on liver, muscle and adipocyte were 270, 56, and 217
respectively.
As the results of functional annotation analysis, lipid metabo-
lism, and transfer were normalized and DNA replication, the ﬁrst
step of cell proliferation, was repressed in the liver on TSOD-
E. In muscle, the repression of the wound response and lipid
synthesis and the enhancement of muscle system process were
observed. In adipocytes, cell cycle, inﬂammatory response, and
immune system development were repressed. These results indi-
cate β-CRX facilitates lipid metabolism in muscle and reduced
adipocyte proliferation and inﬂammatory response.
The expression of PPAR-α were also analyzed (Table 2) and
found the expression reduction on TSOD-C compared to TSNO-
C and it restored on TSOD-E in adipocyte and muscle. In contrast,
PPAR-α expression in liver on TSOD-C is almost the same as
TSNO-C, while it decreased signiﬁcantly on TSOD-E compared
to TSOD-C. These results indicate oral administration of β-CRX
could modulate the expression of PPAR-α. As PPAR-α takes part
in many metabolic pathways including energy metabolism, its
expression modulation could affects diverse biological processes.
The resulting changes might act to prevent obese both directly and
indirectly.
DISCUSSION
Obesity is closely associated with several chronic diseases such as
diabetes, cardiovascular diseases, hyperlipidemia, or hypertension,
well-known symptoms as metabolic syndrome. As metabolic syn-
drome is becoming a serious social problem, many efforts have
been done to reduce it.
Table 1 | Results of DNA microarray analysis on liver, muscle, and
adipocyte.
Number*
of probes
GO term Regulation
Liver 270 Cholesterol metabolic
process
Up/down**
Fatty acid metabolism Up/down**
DNA replication Down
Muscle 56 Response to wounding Down
Cellular lipid synthesis Down
Muscle system process Up
Adipocyte 217 Cell cycle Down
Inﬂammatory response Down
*Number of probes ﬂuctuates the expression >2-times both between TSNO-
C/TSOD-C and betweenTSOD-C/TSOD-E.
**Abnormality of gene expressions was normalized.
Table 2 | Fluctuation of PPAR-α expression.
TSOD-C/TSNO-C TSOD-E/TSOD-C
Liver 0.99 0.55
Adipocyte 0.27 2.13
Muscle 0.32 1.78
We had reported β-CRX administration on mildly obese male
results in visceral fat reduction (Tsuchida et al., 2008). In spite of
the clear results, itsmechanismwas not examined. Consistent with
our previous human study, present report showed β-CRX admin-
istration repressed the elevation of body weight, serum lipid levels,
and adipose tissue weight on TSOD mice. This indicates β-CRX
administration could prevent metabolic syndrome both on mouse
and human.
To identify the anti-obese mechanism, we focused on the vis-
ceral adipose tissue ﬁrst. Adipose tissue has two functions: energy
storage and active endocrine organ and these are closely related.
Mature adipocyte accumulates adequate amount of triglyceride
and secrete several adipokines such as adiponectin or leptin.
Obesity leads over-accumulation of triglyceride to the adipocyte
and the subsequent hypertrophic adipocytes secrete inﬂammatory
messengers such as TNF-α, IL1-β, or IL-10 instead of the beneﬁcial
ones (Rabe et al., 2008). This plays a role in insulin resistance and
deteriorates diabetes or adiposity.
DNA microarray analysis indicates oral administration of β-
CRX could repress the adipocyte proliferation and the inﬂamma-
tory responses by the inhibition of inﬂammatory cytokine secre-
tion. These results are well consistent with the present microscopic
observation.
PPAR is a nuclear receptor identiﬁed inXenopus (Issemann and
Green, 1990). Close relation were known between the upregula-
tion of PPARs and obese or diabetes and they are practically used
as the drug; PPAR-γ agonists are used for diabetes and PPAR-α
agonists are used for serum lipids reduction.
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Werecently reportedβ-CRXcouldnegativelymodulatePPAR-γ
activity in vitro, not by the direct interaction but though the signal-
ing cascade (submitted). In this study, we showed oral administra-
tion of β-CRX on TSOD mice upregulated PPAR-α expression in
adipocyte and muscle, indicating the energy consumption eleva-
tion. As β-CRX also downregulate PPAR-α in the liver of TSOD-E,
it is the opposite change found in obesemodelmice (Memon et al.,
2000) and supposed to be an anti-obese effect.
PPAR-α upregulation could increase energy consumption and
that contributes to the obese prevention. Because PPAR-α is a
nuclear receptor that could affect many cellular and metabolic
processes, it might be possible that PPAR-α could contribute
to obese prevention though the different pathway. One of the
candidates is clock gene-dependent pathway.
We identiﬁed circadian rhythm-related gene expression and
found interesting changes. For example, Bmal1 expression in
adipocyte increased 3.3 times on TSOD-C compared to TSNO-
C, while it decreased to 0.6 time by the β-CRX administration
(data not shown).
Several reports indicate the relation between the circadian
gene regulation, obese and PPARs. For example, Oishi et al.
(2005) showed that PPAR-α agonist could modulate mouse cir-
cadian rhythm. Inoue et al. (2005) reported CLOCK/BMAL1
heterodimer involves in lipid metabolism via transcriptional acti-
vation of PPAR. Another report showed the crosstalk between
CLOCK/BMAL1-regulated and PPARs/RXRα-regulated systems
(Nakamura et al., 2008).
These results suggest the close relation between the circadian
system and the lipid metabolism. Because β-CRX could modu-
late PPAR-α gene expression, it could modulate not only the lipid
metabolism but also the circadian clock gene expression. In this
studywe examined the circadian clock related gene expressiononly
one time point a day. Further investigation, e.g., time-dependent
gene expression surveys or ethological analysis, may reveal new
insight into the relation between circadian regulation and lipid
metabolism or metabolic syndrome.
In this study, we demonstrated oral administration of β-CRX
repressed body weight and adipocyte hypertrophy. They may
prevent reduction of adipokines and escalation of inﬂamma-
tory messengers. Serum lipid repression had also observed and
was well correspond to the microarray analysis. These results
strongly suggest β-CRX might modulate gene expression, prob-
ably via PPAR signaling pathways. Recent ﬁndings indicate the
involvement of the circadian clock genes in fatty acid metabo-
lism or adiposity (Inoue et al., 2005; Oishi et al., 2005). Although
we only analyzed circadian gene expression at one time point
a day, β-CRX could modulate or normalize them through the
regulation of PPARs and result in obese prevention. Detailed
research may reveal the correlation between obesity and circadian
control.
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